Pair Name	Daurinoline, Sorafenib
Disease Info	[ICD-11: 2C12]	Hepatocellular carcinoma		Investigative
Biological Phenomena	Inhibition-->Vasculogenic mimicry
Gene Regulation	Down-regulation	Phosphorylation	AKT1	hsa207
	Up-regulation	Expression	BAX	hsa581
	Down-regulation	Expression	BCL2	hsa596
	Up-regulation	Cleavage	CASP3	hsa836
	Up-regulation	Cleavage	CASP9	hsa842
	Down-regulation	Expression	CCND1	hsa595
	Down-regulation	Expression	CCNE1	hsa898
	Down-regulation	Expression	CDK2	hsa1017
	Down-regulation	Expression	CDK4	hsa1019
	Up-regulation	Expression	CDKN1A	hsa1026
	Down-regulation	Expression	KDR	hsa3791
	Down-regulation	Phosphorylation	MAPK1	hsa5594
	Down-regulation	Phosphorylation	MAPK3	hsa5595
	Up-regulation	Cleavage	PARP1	hsa142
	Up-regulation	Expression	PSMD9	hsa5715
	Down-regulation	Activity	RHOA	hsa387
	Down-regulation	Activity	ROCK2	hsa9475
In Vitro Model	QGY-7703	Human papillomavirus-related cervical adenocarcinoma	Homo sapiens (Human)	CVCL_6715
	MHCC97-H	Adult hepatocellular carcinoma	Homo sapiens (Human)	CVCL_4972
In Vivo Model	MHCC-97H cells were suspended in cold PBS at a density of 1×10⁷ cells/ml, and 100 μl of the cell suspension was subcutaneously injected into the right flank of each mouse.
Result	Our study provides insights into the molecular mechanisms underlying DS-induced inhibition of VM, which may facilitate the development of a novel clinical anti-HCC drug. Moreover, our findings suggest that the combination of DS and sorafenib constitutes a potential therapeutic strategy for HCC.